Barry Borlaug, ACC 2023: An overview of sodium-glucose co-transporter 2 inhibitors in patients with heart failure
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have displayed clinical significance reductions in the risk of heart failure hospitalizations. In this touchCARDIO interview, we speak with Dr Barry Borlaug (Mayo Clinic, Rochester, MN, USA) to discuss clinical trials using SGLT2is in patients with heart failure.
Dr Borlaug presented an abstract entitled ‘Evaluation Of The Mechanism Of Benefit For Dapagliflozin In Heart Failure With Preserved Ejection Fraction: An Invasive Hemodynamic Randomized Trial’ at ACC.23 Together With WCC (ACC.23/WCC) in New Orleans, 4–6 March 2023
Click here to view Dr Borlaug’s video on the hemodynamic randomized trial
What have previous clinical trials taught us about sodium-glucose co-transporter 2 inhibitors (SGLT2i) and what questions remain unanswered? (0:17)
Disclosures: Barry Borlaug is a consultant for Aria, Boehringer Ingelheim, Edwards, Eli Lilly, Imbria, Merck and VADovations, and has received grant/research support from Astra Zeneca, Corvia, GlaxoSmith Kline, Medtronic, Mesoblast, NIH/NHLBI, Novo Nordisk and Tenax.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ACC 2023
Access more content on Heart Failure here
My name is Barry Borlaug. I’m a cardiologist and Professor of Medicine at Mayo Clinic in Rochester, Minnesota.
Q: What have previous clinical trials taught us about sodium-glucose co-transporter 2 inhibitors (SGLT2i) and what questions remain unanswered?
Well, it’s a good question. I mean, SGLT2 inhibitors were really discovered by serendipity because the FDA required large trials to show cardiovascular safety and they were serendipitously shown to reduce the risk of heart failure. That was then later tested prospectively in patients with heart failure with reduced ejection fraction, and then most recently in patients with heart failure with preserved ejection fraction (HFpEF).
And across the board, we have seen a significant and clinically meaningful reduction in the risk of heart failure hospitalizations, the combined endpoint of heart failure hospitalization and cardiovascular death. These drugs also improve quality of life and there’s some evidence that they improve functional capacity as well in patients with HFpEF. But like I said, they were discovered serendipitously. Although there is a lot of speculation about the mechanism of benefit, no one really knows and that’s an important sort of unmet need that we need to fill.
Subtitles and transcript are autogenerated
Share this Video
Related Videos In Heart Failure
John Boehmer, ACC 2023: The MicrocorTM device for heart failure management, the BMAD trial
Rates of readmission following heart failure hospitalization are high. The BMAD trial in patients with heart failure assessed the use of the Microcor device on readmission rates. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA) to discuss purpose, […]
John Boehmer, ACC 2023: The MicrocorTM device, monitoring tool for heart failure
The most common cause of hospital admission due to heart failure is due to excess fluid retention. The MicrocorTM device monitors fluid levels in the lungs to aid in patient management. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, […]
Barry Borlaug, ACC 2023: Dapagliflozin in heart failure, an invasive hemodynamic randomized trial
Heart failure with preserved ejection fraction (HFpEF) is a hemodynamic disorder characterized by an elevation of left ventricular filling pressures. This trial assessed the ability of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), to reduce this elevation. In this touchCARDIO interview, we speak with Dr Barry Borlaug (Mayo Clinic, Rochester, MN, USA) to discuss the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!